Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

pancreatic neoplasms/fatigue

リンクがクリップボードに保存されます
ページ 1 から 293 結果

Evaluation of fatigue in patients with pancreatic cancer receiving chemotherapy treatment: a cross-sectional observational study.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE Cancer-related fatigue (CRF) is one of the most common symptoms experienced by cancer patients (CPs) and negatively affects quality of life. Although CRF is frequently experienced, it is often underreported, underdiagnosed and undertreated. The objectives of this study were to evaluate the

Role of methylphenidate in the treatment of fatigue in advanced pancreatic cancer population.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND Fatigue is a common but devastating symptom for advanced pancreatic cancer (APC) patients. To date, no proven treatment exists. Methylphenidate (MPH) showed inconsistent results in treating other cancer related fatigue. We performed a retrospective study to assess MPH in ameliorating

Weight Loss, Diabetes, Fatigue, and Depression Preceding Pancreatic Cancer.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
We aimed to determine the severity and co-occurrence of established and potential paraneoplastic conditions in pancreatic cancer (weight loss, new onset diabetes, fatigue, and depression) and their relation to patient characteristics. Using information from personal interviews with 510 cases and 463

Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE Cyclooxygenase-2 (COX-2) has been shown to be expressed in a variety of tumors including pancreatic cancer. The combination of gemcitabine and irinotecan is active in pancreatic cancer. The purpose of this study is to determine the toxicity and response rate to the addition of the
UNASSIGNED To study the safety and clinical efficacy on combination of irreversible electroporation and allogeneic natural killer cell therapy for treating Stage III/IV pancreatic cancer, evaluating median progression free survival (PFS), and overall survival (OS). UNASSIGNED Adverse events of all
BACKGROUND Dose modifications following adverse events (AEs) are an important part of the management of patients with pancreatic cancer treated with chemotherapy. While dose modifications are utilized to ensure patient safety, the subsequent influence of dose adjustments on treatment exposure and

Symptom profiles and palliative care in advanced pancreatic cancer: a prospective study.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE To describe prospectively the prevalence and severity of disease-related symptoms, quality of life (QOL) and need for palliative care in patients with advanced pancreatic cancer. METHODS Fifty-one patients treated for advanced pancreatic cancer filled in the Edmonton Symptom Assessment

Exercise as medicine in the management of pancreatic cancer: a case study.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND Given the poor prognosis for patients diagnosed with pancreatic cancer, therapies that enhance the ability to tolerate adjuvant treatments, reduce the loss of physical functioning and optimize quality of life are critically important. Exercise may represent such a therapy; however, no

Symptom management for patients with pancreatic cancer.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Patients with pancreatic cancer have multiple symptoms from both disease and treatment. Pain, anorexia, nausea, vomiting, weight loss, fatigue, pruritus, and dyspnea are the most common symptoms. Until better treatments are found, patients with pancreatic cancer need effective symptom management to

[Relationship between symptoms of pancreatic cancer-related depression and quality of life of patients].

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE To investigate the relationship between symptoms of pancreatic cancer-related depression and quality of life of patients. METHODS Fifty inpatients with pancreatic cancer from 3 Guangzhou hospitals between June 2007 and October 2008 were enrolled. Hamilton rating scale for depression-24
The patient was a 70-year-old man with metastatic pancreatic cancer. After he received combination chemotherapy with gemcitabine and oral S-1 on day 1, he experienced severe general fatigue, anorexia and nausea. Then we changed the dose of gemcitabine from 1,000 mg/m(2) 2 to 500 mg/m(2) according to

Survivorship after treatment of pancreatic cancer: insights via an Internet-based survivorship care plan tool.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Pancreatic cancer survivors face a unique set of challenges in survivorship, yet structured survivorship care planning is lacking in practice. Survivorship care plans (SCPs) are an essential part of quality cancer care and can facilitate the transition following active treatment; the use of SCPs in

[Outcomes of treatment with gemcitabine for unresectable pancreatic cancer].

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
The efficacy and safety of gemcitabine were investigated in 16 patients with unresectable pancreatic cancer (Arm A), compared with 16 patients who received chemotherapy without gemcitabine (Arm B) and 44 patients who received best supportive care (Arm C). A gemcitabine 30 min i.v. infusion at a

[A Case of Conversion Surgery for an Initially Locally Advanced Unresectable Pancreatic Cancer after S-1 Chemotherapy].

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
We report a case of conversion surgery for a locally advanced unresectable(UR-LA)pancreatic cancer that was radically resected after S-1 therapy. A 65-year-old man visited a referral physician because of fatigue and liver dysfunction. A CT scan revealed a mass in the pancreatic uncinate process that
OBJECTIVE To evaluate the efficacy and tolerance of the docetaxel/gefitinib combination as second-line treatment in patients with advanced pancreatic cancer. METHODS Twenty-six patients pretreated with gemcitabine-based chemotherapy were enrolled in the study. Docetaxel (75 mg/m(2), i.v.) was
Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge